Erdurmus Mesut, Totan Yuksel
Department of Ophthalmology, Fatih University Medical School, Alparslan Turkes Cad No: 57, 06510 Emek, Ankara, Turkey.
Graefes Arch Clin Exp Ophthalmol. 2007 Oct;245(10):1577-9. doi: 10.1007/s00417-007-0587-4. Epub 2007 Apr 26.
To report the efficacy of subconjunctival bevacizumab injection in patients with corneal neovascularization (NV).
This retrospective interventional case study included two eyes of two patients with corneal NV due to aqueous-deficient dry eye with filamentary keratitis in the first case, and corneal graft failure in the second case. Patients received a subconjunctival injection of 2.5 mg (0.1 ml) bevacizumab. Morphologic changes were investigated by slit-lamp biomicroscopy and corneal photography.
Corneal NV was dramatically regressed a week after injection in the first case. In the second case, minor vessels were regressed while the major one did not. No infection or inflammation was observed. No relapse was seen within the follow-up of two to three months.
Subconjunctival injection of bevacizumab may offer an additional strategy for the treatment of corneal NV.
报告结膜下注射贝伐单抗治疗角膜新生血管（NV）患者的疗效。
本回顾性干预性病例研究包括2例患者的2只眼，第1例因泪液缺乏性干眼症合并丝状角膜炎导致角膜NV，第2例因角膜移植失败导致角膜NV。患者接受结膜下注射2.5 mg（0.1 ml）贝伐单抗。通过裂隙灯显微镜检查和角膜照相术研究形态学变化。
第1例患者注射后1周角膜NV显著消退。第2例患者小血管消退，而大血管未消退。未观察到感染或炎症。在2至3个月的随访期内未见复发。
结膜下注射贝伐单抗可能为角膜NV的治疗提供一种额外的策略。
